Recently, the 115th Annual Meeting of the American Association for Cancer Research (AACR) 2024 annual meeting concluded in San Diego. As the annual event in the field of cancer research, the plenary sessions each year are the focus of attention. This year, the application of artificial intelligence in oncology became a hot topic of discussion at AACR undoubtedly.

AACR Focuses on Artificial Intelligence, Embarking on a Journey of AI-Driven Medical Innovation

In the medical field of the twenty-first century, deep learning, as a cutting-edge artificial intelligence technology, is gradually emerging, especially in cancer research. It revolutionarily connects traditional pathological analysis with the detailed information of molecular biology, bringing new possibilities for cancer diagnosis and treatment strategies. Impressively, the AACR opening plenary session invited four distinguished cancer scientists to speak around the core theme of the 2024 annual meeting, "Inspiring Science, Advancing Progress, Innovating Treatment". Among the only four topics, artificial intelligence occupied two sections.

Dr. Agiv Regev, the keynote speaker, provided an in-depth analysis of the new perspectives and potential impacts that cell atlases bring to cancer biology and novel therapies. She stated that the innovation of single-cell genomics technology has greatly propelled research in the past few years, enabling scientists to delve into an increasing number of cells. The explosive growth of these data has allowed AI to infer complex genetic information from simple tools, and demonstrated tremendous potential in drug screening and gene perturbation analysis.

The speaker, Dr. Jakob Nikolas Kather, discussed how artificial intelligence can extract biomarkers from regular pathological sections accurately. He believes that AI can integrate data from multiple dimensions for judgment, such as pathological images, radiographic images, natural language, genetic data, and more. The latest AI technologies are solving problems that were difficult or impossible to resolve previously. Dr. Kather enthusiastically stated, "We are in an exciting era where the field of AI is developing rapidly. Our mission is to apply these cutting-edge technologies to tackle medical challenges and benefit patients directly."

Dr. Victor E. Velculescu, the chair of the Annual Meeting Education Committee, stated that artificial intelligence and big data science are revolutionizing medicine, especially in the fields of precision oncology, immunology, molecular biology, and cancer prevention. However, despite the unprecedented speed of integration between AI and oncology, the construction of models still needs the support of massive amounts of data. Large language models such as GPT-4 have attempted to enter the clinical field, but their current effectiveness is limited and they require more information and data to be fed. Yet, it may only take one year before we see the superior AI tool shine in clinical practice. This tool will integrate clinical guidelines, research literature, genetic data, and clinical information for comprehensive analysis, thereby providing precise diagnostic and treatment recommendations, truly ushering medical practice into a new era of intelligence.

SmartMTB is Positioned at the Forefront, Leading the Field of AI in Healthcare

An increasing number of AI models are being applied to tumor diagnosis, classification, prediction of treatment responses, and prognosis. However, the real application of AI relies on the support of deep learning and large datasets. At the AACR opening session, experts envisioned the future of AI in healthcare, and OrigiMed has turned these visions into reality. As a leading company in the field of innovative technologies and applications for precision oncology, OrigiMed has been dedicated to medical innovation. Driven by years of strategic planning and AI technology, OrigiMed is realizing intelligent applications across multiple scenarios.

In 2023, various AIGC models, represented by ChatGPT, have emerged and been applied across various industries. OrigiMed took the lead in launching the world's first AI-based precision medicine assistant—SmartMTB. It is based on a large language model and a proprietary database (OrigiMed's own 600+ tumor subtypes, 640,000+ knowledge entries, 2,000+ drug information, and 460,000+ clinical trial data) and is trained by reinforcement learning, to ensure the quality, accuracy, and reliability of the model. Users can switch between "Oncology (Oncology-related Consultation)," "HealthCare (Daily Health Consultation)," and "Report Decoder (Analysis of Various Examination Reports)" modes, and through conversational communication, obtain intelligent answers to various complex scenarios, meeting different health needs.

SmartMTB, as a blockbuster AI product of OrigiMed, made a stunning appearance at this year's AACR, attracting the attention of scholars worldwide and making the world take a fresh look at the power of AI in Chinese. Research results indicate that the answers provided by SmartMTB have exceeded ChatGPT-4.0 in terms of accuracy, relevance, and personalization. Particularly in interpreting NGS reports, expert consensus score on key points exceeds 80%, demonstrating exceptional professional proficiency. Beyond that, our scientists are continuously updating and upgrading SmartMTB through automated tools and the latest medical research, ensuring that it remains in a state of wisdom, excellence, and authority.

The new generation of artificial intelligence is a driving force for the leapfrog development and optimization of medicine. In the future, OrigiMed will continue to deepen the construction of corporate digital capabilities, striving to create more valuable AI application solutions, exploring the infinite possibilities of AI in healthcare, and achieving more innovative breakthroughs in the field of precision diagnosis and treatment, and contributing more to the development of global medical technology.